REPLIGEN CORP Sales Revenue, Goods, Net (Deprecated 2018-01-31)
REPLIGEN CORP (RGEN) reported Sales Revenue, Goods, Net (Deprecated 2018-01-31) of $44.80 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-08.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SalesRevenueGoodsNet · last filed 2018-05-08
- REPLIGEN CORP sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $44.80M, a 46.55% increase year-over-year.
- REPLIGEN CORP sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $41.57M, a 63.03% increase year-over-year.
- REPLIGEN CORP sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $36.51M, a 47.97% increase year-over-year.
- REPLIGEN CORP sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $32.43M, a 11.19% increase year-over-year.
- REPLIGEN CORP sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2017 was $141.09M, a 35.09% increase from fiscal 2016.
- REPLIGEN CORP sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2016 was $104.44M, a 25.02% increase from fiscal 2015.
- REPLIGEN CORP sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2015 was $83.54M, a 38.24% increase from fiscal 2014.
- REPLIGEN CORP sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2014 was $60.43M, a 27.27% increase from fiscal 2013.
| Period end | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 3 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 3 month as first filed | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 6 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 6 month as first filed | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 9 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 9 month as first filed | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 12 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2018-03-31 | $44.80M 10-Q · filed 2018-05-08 | $86.37M derived: sum of 2 quarters · filed 2018-05-08 | $122.89M derived: sum of 3 quarters · filed 2018-05-08 | $155.32M derived: sum of 4 quarters · filed 2018-05-08 | ||||
| 2017-12-31 | $41.57M 10-K · filed 2018-02-22 | $78.09M derived: sum of 2 quarters · filed 2018-02-22 | $110.52M derived: sum of 3 quarters · filed 2018-02-22 | $141.09M 10-K · filed 2018-02-22 | ||||
| 2017-09-30 | $36.51M 10-K · filed 2018-02-22 | $68.95M derived: sum of 2 quarters · filed 2018-02-22 | $99.52M 10-Q · filed 2017-11-09 | $125.02M derived: sum of 4 quarters · filed 2018-05-08 | ||||
| 2017-06-30 | $32.43M 10-K · filed 2018-02-22 | $63.00M 10-Q · filed 2017-08-03 | $88.50M derived: sum of 3 quarters · filed 2018-05-08 | $113.18M derived: sum of 4 quarters · filed 2018-05-08 | ||||
| 2017-03-31 | $30.57M 10-Q · filed 2018-05-08 | $56.07M derived: sum of 2 quarters · filed 2018-05-08 | $80.75M derived: sum of 3 quarters · filed 2018-05-08 | $109.92M derived: sum of 4 quarters · filed 2018-05-08 | ||||
| 2016-12-31 | $25.50M 10-K · filed 2018-02-22 | $50.18M derived: sum of 2 quarters · filed 2018-02-22 | $79.35M derived: sum of 3 quarters · filed 2018-02-22 | $104.44M 10-K · filed 2018-02-22 | ||||
| 2016-09-30 | $24.68M 10-K · filed 2018-02-22 | $53.85M derived: sum of 2 quarters · filed 2018-02-22 | $78.94M 10-Q · filed 2017-11-09 | $100.39M derived: sum of 4 quarters · filed 2018-02-22 | ||||
| 2016-06-30 | $29.17M 10-Q · filed 2017-08-03 | $54.27M 10-Q · filed 2017-08-03 | $75.71M derived: sum of 3 quarters · filed 2018-02-22 | $95.53M derived: sum of 4 quarters · filed 2018-02-22 | ||||
| 2016-03-31 | $25.09M 10-K · filed 2018-02-22 | $46.54M derived: sum of 2 quarters · filed 2018-02-22 | $66.36M derived: sum of 3 quarters · filed 2018-02-22 | $87.81M derived: sum of 4 quarters · filed 2018-02-22 | ||||
| 2015-12-31 | $21.45M 10-K · filed 2017-02-23 | $41.26M derived: sum of 2 quarters · filed 2017-02-23 | $62.72M derived: sum of 3 quarters · filed 2017-02-23 | $83.54M 10-K · filed 2018-02-22 | ||||
| 2015-09-30 | $19.81M 10-K · filed 2017-02-23 | $41.27M derived: sum of 2 quarters · filed 2017-02-23 | $62.09M 10-Q · filed 2016-11-03 | $77.48M derived: sum of 4 quarters · filed 2017-02-23 | ||||
| 2015-06-30 | $21.46M 10-K · filed 2017-02-23 | $21.46M 10-Q · filed 2015-08-06 | $42.27M 10-Q · filed 2016-08-04 | $42.27M 10-Q · filed 2015-08-06 | $57.67M derived: sum of 3 quarters · filed 2017-02-23 | $72.82M derived: sum of 4 quarters · filed 2017-02-23 | ||
| 2015-03-31 | $20.82M 10-K · filed 2017-02-23 | $20.82M 10-Q · filed 2015-05-08 | $36.21M derived: sum of 2 quarters · filed 2017-02-23 | $51.36M derived: sum of 3 quarters · filed 2017-02-23 | $66.91M derived: sum of 4 quarters · filed 2017-02-23 | |||
| 2014-12-31 | $15.39M 10-K · filed 2016-02-25 | $30.55M derived: sum of 2 quarters · filed 2016-02-25 | $46.10M derived: sum of 3 quarters · filed 2016-02-25 | $60.43M 10-K · filed 2017-02-23 | $60.43M 10-K · filed 2015-03-17 | |||
| 2014-09-30 | $15.15M 10-K · filed 2016-02-25 | $15.15M 10-Q · filed 2014-11-07 | $30.70M derived: sum of 2 quarters · filed 2016-02-25 | $45.04M 10-Q · filed 2015-11-05 | $45.04M 10-Q · filed 2014-11-07 | $55.39M derived: sum of 4 quarters · filed 2016-02-25 | ||
| 2014-06-30 | $15.55M 10-K · filed 2016-02-25 | $15.55M 10-Q · filed 2014-08-11 | $29.89M 10-Q · filed 2015-08-06 | $40.24M derived: sum of 3 quarters · filed 2016-02-25 | $52.42M derived: sum of 4 quarters · filed 2016-02-25 | |||
| 2014-03-31 | $14.34M 10-K · filed 2016-02-25 | $14.33M 10-Q · filed 2014-05-09 | $24.68M derived: sum of 2 quarters · filed 2016-02-25 | $36.87M derived: sum of 3 quarters · filed 2016-02-25 | $49.88M derived: sum of 4 quarters · filed 2016-02-25 | |||
| 2013-12-31 | $10.35M 10-K · filed 2015-03-17 | $22.53M derived: sum of 2 quarters · filed 2015-03-17 | $35.55M derived: sum of 3 quarters · filed 2015-03-17 | $47.48M 10-K · filed 2016-02-25 | $47.48M 10-K · filed 2014-03-14 | |||
| 2013-09-30 | $12.18M 10-K · filed 2015-03-17 | $12.18M 10-Q · filed 2013-11-08 | $25.20M derived: sum of 2 quarters · filed 2015-03-17 | $37.13M 10-Q · filed 2014-11-07 | $46.84M derived: sum of 4 quarters · filed 2015-03-17 | |||
| 2013-06-30 | $13.01M 10-K · filed 2015-03-17 | $13.01M 10-Q · filed 2013-08-07 | $24.95M 10-Q · filed 2014-08-11 | $34.66M derived: sum of 3 quarters · filed 2015-03-17 | $45.78M derived: sum of 4 quarters · filed 2015-03-17 | |||
| 2013-03-31 | $11.93M 10-K · filed 2015-03-17 | $11.93M 10-Q · filed 2013-05-07 | $21.64M derived: sum of 2 quarters · filed 2015-03-17 | $32.77M derived: sum of 3 quarters · filed 2015-03-17 | $44.43M derived: sum of 4 quarters · filed 2015-03-17 | |||
| 2012-12-31 | $9.71M 10-K · filed 2014-03-14 | $20.83M derived: sum of 2 quarters · filed 2014-03-14 | $32.49M derived: sum of 3 quarters · filed 2014-03-14 | $41.83M 10-K · filed 2015-03-17 | ||||
| 2012-09-30 | $11.12M 10-K · filed 2014-03-14 | $11.12M 10-Q · filed 2012-11-08 | $22.78M derived: sum of 2 quarters · filed 2014-03-14 | $32.13M 10-Q · filed 2013-11-08 | $35.24M derived: sum of 4 quarters · filed 2014-03-14 | |||
| 2012-06-30 | $11.66M 10-K · filed 2014-03-14 | $11.66M 10-Q · filed 2012-08-09 | $21.00M 10-Q · filed 2013-08-07 | $24.11M derived: sum of 3 quarters · filed 2014-03-14 | $29.86M derived: sum of 4 quarters · filed 2014-03-14 | |||
| 2012-03-31 | $9.34M 10-K · filed 2014-03-14 | $9.34M 10-Q · filed 2012-05-10 | $12.46M derived: sum of 2 quarters · filed 2014-03-14 | $18.20M derived: sum of 3 quarters · filed 2014-03-14 | $22.56M derived: sum of 4 quarters · filed 2014-03-14 | |||
| 2011-12-31 | $3.11M 10-K · filed 2013-03-15 | $8.86M derived: sum of 2 quarters · filed 2013-03-15 | $13.22M 10-K · filed 2014-03-14 | $16.36M derived: sum of 4 quarters · filed 2013-03-15 | ||||
| 2011-09-30 | $5.74M 10-K · filed 2013-03-15 | $5.74M 10-Q · filed 2011-11-09 | $10.10M 10-Q · filed 2011-11-09 | $13.25M 10-Q · filed 2012-11-08 | $16.38M derived: sum of 4 quarters · filed 2014-03-14 | |||
| 2011-06-30 | $4.36M 10-K · filed 2013-03-15 | $4.36M 10-Q · filed 2011-08-05 | $7.51M 10-Q · filed 2012-08-09 | $10.64M derived: sum of 3 quarters · filed 2014-03-14 | $15.05M derived: sum of 4 quarters · filed 2014-03-14 | |||
| 2011-03-31 | $3.15M 10-K · filed 2013-03-15 | $3.15M 10-Q · filed 2012-05-10 | $6.28M derived: sum of 2 quarters · filed 2014-03-14 | $10.69M derived: sum of 3 quarters · filed 2014-03-14 | $14.96M 10-K · filed 2013-03-15 | |||
| 2010-12-31 | $3.13M derived: 10-K 9 month − 10-Q 6 month · filed 2014-03-14 | $7.54M derived: sum of 2 quarters · filed 2014-03-14 | $11.81M 10-K · filed 2014-03-14 | |||||
| 2010-09-30 | $4.42M 10-Q · filed 2011-11-09 | $8.68M 10-Q · filed 2011-11-09 | ||||||
| 2010-06-30 | $4.27M 10-Q · filed 2011-08-05 | |||||||
| 2010-03-31 | $10.30M 10-K · filed 2012-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |